XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
  Mental Health
  Aging
  Events
  Parenting
  Fitness
  Food & Nutrition
  Happiness
  Sleep Hygiene
  Occupational Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Health Channel
subscribe to Health newsletter

Medical News : Health

   DISCUSS   |   EMAIL   |   PRINT
US approves inhaler for adult diabetic patients
Jan 31, 2006, 18:48, Reviewed by: Dr. Priya Saxena

The FDA, which approved it Friday, said the safety and efficacy of Exubera, the first new delivery system for insulin since it was developed some 80 years ago, have been studied in approximately 2,500 adult patients with type 1 and type 2 diabetes.


 
The US Food and Drug Administration (FDA) has approved an inhaler that could instantly regulate blood sugar level, bringing relief to the adults suffering from diabetes.

The hand-held Exubera inhaler is a rapid-acting, dry powder human insulin that is inhaled through the mouth prior to eating.

It weighs four ounces and, when closed, is about the size of an eyeglass case. The unique inhaler produces in its chamber a cloud of insulin powder, which is designed to pass rapidly into the bloodstream to regulate the body's blood sugar levels, reported health portal MedPage Today.

The FDA, which approved it Friday, said the safety and efficacy of Exubera, the first new delivery system for insulin since it was developed some 80 years ago, have been studied in approximately 2,500 adult patients with type 1 and type 2 diabetes.

In clinical studies, peak insulin levels were achieved at 49 minutes (range 30 to 90 minutes) with Exubera inhaled insulin, compared to 105 minutes (range 60 to 240 minutes) for short-acting insulin, it said.

However smokers or those who quit smoking in the past six months should not use Exubera, the FDA said. It was also contraindicated for patients with asthma, bronchitis, or emphysema.
 

- Indo-Asian News Service
 

 
Subscribe to Health Newsletter
E-mail Address:

 



Related Health News

Mental health problems threaten the knowledge economy
Raine Study: Breastfeeding boosts mental health
The need for "exercise prescriptions."
Sleep-related breathing disorder can increase risk of depression
Mandarin oranges decrease liver cancer risk,atherosclerosis
The future of plastic surgery
Parents drink, Suffer the Children
University of Pittsburgh to host Global Health Conference
IOF to launch 'Bone App�tit' campaign on October 20
Online video games found to promote sociability


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us